Fisher & Paykel Healthcare Corporation Limited announced at its annual shareholders’ meeting today that it has commenced planning for its third manufacturing facility in Mexico, which is to be commissioned within the next two years.
“As indicated in June we are continuing to grow manufacturing capacity to ensure a further increase in supply of our respiratory products is available if required. To expedite availability, the company is utilising its existing infrastructure and property in Tijuana, Mexico,” said Managing Director and CEO Lewis Gradon.
The company completed its second Mexico facility in January 2019 and its fourth New Zealand facility, the Daniell Building, in May 2020. Together with the planned new Mexico building, these three buildings add an additional 17,000 m2 of cleanroom manufacturing space, to a base of 28,400 m2 available prior to their construction.
Board subcommittee appointments
As announced in November last year, Board chair Tony Carter retires from the Board with effect from the close of today’s annual shareholders’ meeting. Current director Scott St John succeeds Mr Carter as chair and has also been appointed as a member of the company’s Quality, Safety & Regulatory Committee.
The company also announced that the Board has appointed current director Neville Mitchell to replace Scott St John as chair of the Audit & Risk Committee from the conclusion of the meeting. Mr Mitchell is considered by the Board to be an independent director. He is the former CFO of Cochlear Limited and has been a Board member of Fisher & Paykel Healthcare since November 2018.
The company has provided the Chair’s speech, CEO’s speech and slide presentation for the 2020 Annual Shareholders’ Meeting to the NZX and ASX today.
The Annual Shareholders’ Meeting is scheduled to begin at 2pm NZST, 12pm AEST (10pm USEDT) and will be a virtual-only meeting broadcast over the internet. To view the webcast, go to: www.virtualmeeting.co.nz/fph20
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
Authorised by Fisher & Paykel Healthcare Corporation Limited’s Board of Directors